Founder of 23andme Ann Wajiki wins the norms of the DNA test

Written by Sidhi Mahawal and Mariam Sunny

(Reuters) -Anne Wagiki is scheduled to regain control of 23ndme after a $ 305 million offer that controls the Regeneron Pharmaceuticals offer for DNA testing at the bankruptcy auction.

Last month, Regeneron agreed to buy the company for $ 256 million, as it reached a $ 146 million offer from WoJCICKKI and TTAM Non -Purful Research Institute.

The company said on Friday that the deal is expected to be closed in the coming weeks after a court hearing on June 17.

Once on Trailblazer in the original DNA test, 23andme submitted a bankruptcy in March, in an effort to sell its business at an auction after the demand for the demand and the violation of 2023 data that has been subjected to genetic information and a sensitive personality to millions of customers.

TTAM said on Friday that he will support the current privacy policies of 23andme and comply with all the applicable data protection laws.

Earlier this week, New York and more than twenty American states filed a lawsuit against 23andme to challenge the sale of private information to its customers.

The Banking Court in the United States of the Eastern Region from Missouri supervised the bidding process.

Regeneron said he was ready to make a new offer, but he wanted to disintegrate fees of $ 10 million if the WoJCICKKI offer was accepted at the end.

(Byedhi Mahatle and Manya started;